BC
ADMA icon

Burleson & Co’s ADMA Biologics ADMA Stock Holding History

Burleson & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$48.1K Hold
12,407
– – 0.01% 181
2022
Q3 		$30K Hold
12,407
– – 0.01% 224
2022
Q2 		$25K Hold
12,407
– – 0.01% 222
2022
Q1 		$23K Hold
12,407
– – ﹤0.01% 222
2021
Q4 		$17K Hold
12,407
– – ﹤0.01% 237
2021
Q3 		$14K Buy
12,407
+7,407
+148% +$10.4K ﹤0.01% 246
2021
Q2 		$8K Hold
5,000
– – ﹤0.01% 273
2021
Q1 		$9K Buy
+5,000
New +$11.4K ﹤0.01% 257

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Burleson & Co's ADMA Position: Q4 2022 in Review

Burleson & Co held its ADMA Biologics (ADMA) position steady in Q4 2022 at 12,407 shares worth $48.1K. The position accounts for 0.01% of the portfolio, ranked #181.

Burleson & Co first reported a position in ADMA in Q1 2021 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold ADMA as of Q4 2022.

  • Burleson & Co held 12,407 shares of ADMA Biologics worth $48.1K as of Q4 2022.
  • Burleson & Co left its ADMA Biologics share count unchanged in Q4 2022.
  • ADMA Biologics made up 0.01% of Burleson & Co's portfolio in Q4 2022, its #181 holding.
  • Burleson & Co first reported a position in ADMA Biologics in Q1 2021 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.